Grant name: Blueprint Neurotherapeutics Network (BPN)
Funding organization: National Institutes of Health (NIH)
Total funding amount: Not specified
Duration: Up to 5 years (1 year for UG3 phase, up to 4 years for UH3 phase)
Primary objective: Advance small molecule drug discovery and development projects into clinical settings.
Key stakeholders: Neuroscience investigators, NIH consultants, CROs.
Funding source: NIH.
Funding type: Cooperative Agreement.
Significance: Supports drug discovery in neuroscience, filling a gap in resources for academic labs and small companies.
Grant frequency: Recurring.
Eligible organization types: Higher Education Institutions, Nonprofits, For-Profit Organizations, Local Governments, State Governments, County Governments, City or Township Governments, Indian/Native American Tribal Governments, Federal Government, Foreign Organizations.
Specific qualifications: Not specified.
Geographic location requirements: Not specified.
Track record: Not specified.
Partnership requirements: Collaboration with NIH consultants and CROs is encouraged.
Inclusivity and diversity considerations: Not specified.
Previous relationship with funder: Not specified.
Primary focus areas: Small molecule drug discovery and development for nervous system disorders.
Target sectors: Neuroscience, pharmacology.
Expected outcomes: Development of drug candidates through IND-enabling studies and Phase I clinical testing.
Sustainability expectations: Not specified.
Technical expertise: Experience in medicinal chemistry and drug development.
Infrastructure requirements: Access to laboratories and necessary research tools.
Quality standards: Compliance with Good Manufacturing Practices (GMP) and FDA standards.
Risk management: Not specified.
Budget range: Not specified.
Eligible costs: Costs associated with drug discovery and development activities.
Matching fund requirements: Not specified.
Payment schedule: Not specified.
Financial reporting requirements: Not specified.
Application deadlines: New applications due by 5:00 PM local time on specified dates.
Earliest start date: January 27, 2025.
Expiration date: August 19, 2026.
Regulatory compliance requirements: Must adhere to NIH policies and FDA regulations.
Data protection regulations: Not specified.
Required documentation: Follow instructions in the Research Instructions in the How to Apply - Application Guide.
Application procedure: Submit through Grants.gov or NIH ASSIST system.
Evaluation criteria: Based on scientific merit and alignment with NIH priorities.
Potential challenges: High attrition rates in drug development.
Innovation requirements: Projects should propose novel approaches to drug discovery.
Success rate statistics: Not specified.
Emerging priority areas: Focus on neuroscience and small molecule development.